213 related articles for article (PubMed ID: 27853383)
21. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
D'Urzo AD; Rennard SI; Kerwin EM; Mergel V; Leselbaum AR; Caracta CF;
Respir Res; 2014 Oct; 15(1):123. PubMed ID: 25756831
[TBL] [Abstract][Full Text] [Related]
22. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat
Steinmetz KO; Abenhardt B; Pabst S; Hänsel M; Kondla A; Bayer V; Buhl R
Int J Chron Obstruct Pulmon Dis; 2019; 14():1441-1453. PubMed ID: 31308649
[TBL] [Abstract][Full Text] [Related]
23. Reducing and managing chronic obstructive pulmonary disease exacerbations with tiotropium + olodaterol.
Criner G; Duffy S
Curr Med Res Opin; 2021 Feb; 37(2):275-284. PubMed ID: 33095662
[TBL] [Abstract][Full Text] [Related]
24. Drugs for COPD.
Med Lett Drugs Ther; 2020 Sep; 62(1606):137-144. PubMed ID: 32960872
[No Abstract] [Full Text] [Related]
25. Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease.
Ramadan WH; Kabbara WK; El Khoury GM; Al Assir SA
Int J Chron Obstruct Pulmon Dis; 2015; 10():2347-56. PubMed ID: 26586940
[TBL] [Abstract][Full Text] [Related]
26. Improvement In Self-Reported Physical Functioning With Tiotropium/Olodaterol In Central And Eastern European COPD Patients.
Valipour A; Tamm M; Kociánová J; Bayer V; Sanzharovskaya M; Medvedchikov A; Haaksma-Herczegh M; Mucsi J; Fridlender Z; Toma C; Belevskiy A; Matula B; Šorli J
Int J Chron Obstruct Pulmon Dis; 2019; 14():2343-2354. PubMed ID: 31632003
[TBL] [Abstract][Full Text] [Related]
27. An update on LAMA/LABA combinations for COPD.
Drug Ther Bull; 2017 Jan; 55(1):2-5. PubMed ID: 28057707
[TBL] [Abstract][Full Text] [Related]
28. Tiotropium/Olodaterol: A Review in COPD.
Dhillon S
Drugs; 2016 Jan; 76(1):135-46. PubMed ID: 26683033
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi.
Calzetta L; Rogliani P; Mattei M; Alfonsi P; Cito G; Pistocchini E; Cazzola M; Matera MG
COPD; 2017 Oct; 14(5):526-532. PubMed ID: 28745522
[TBL] [Abstract][Full Text] [Related]
30. Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD.
Pelaia G; Vatrella A; Busceti MT; Gallelli L; Calabrese C; Terracciano R; Lombardo N; Maselli R
Ther Clin Risk Manag; 2015; 11():1563-72. PubMed ID: 26504398
[TBL] [Abstract][Full Text] [Related]
31. Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients.
Calzetta L; Matera MG; Cazzola M; Rogliani P
Adv Ther; 2019 Dec; 36(12):3291-3298. PubMed ID: 31654332
[TBL] [Abstract][Full Text] [Related]
32. [Current position of new fixed-dose combination of tiotropium and olodaterol - its role in the treatment of chronic obstructive pulmonary disease in the Czech Republic].
Koblížek V; Svoboda M
Vnitr Lek; 2016; 62(12):1011-1020. PubMed ID: 28139131
[TBL] [Abstract][Full Text] [Related]
33. Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis.
Calzetta L; Di Marco F; Blasi F; Cazzola M; Centanni S; Micheletto C; Rossi A; Rogliani P
Pulm Pharmacol Ther; 2019 Dec; 59():101855. PubMed ID: 31639476
[TBL] [Abstract][Full Text] [Related]
34. Table: Correct Use of inhalers for COPD.
Med Lett Drugs Ther; 2020 Sep; 62(1606):e150-e154. PubMed ID: 32960876
[No Abstract] [Full Text] [Related]
35. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting.
Price D; Keininger D; Costa-Scharplatz M; Mezzi K; Dimova M; Asukai Y; Ställberg B
Respir Med; 2014 Dec; 108(12):1786-93. PubMed ID: 25307414
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO
Ferguson GT; Karpel JP; Clerisme-Beaty E; Grönke L; Voß F; Buhl R
Int J Chron Obstruct Pulmon Dis; 2016; 11():2701-2710. PubMed ID: 27843306
[TBL] [Abstract][Full Text] [Related]
37. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
Sauer R; Hänsel M; Buhl R; Rubin RA; Frey M; Glaab T
Int J Chron Obstruct Pulmon Dis; 2016; 11():891-8. PubMed ID: 27217742
[TBL] [Abstract][Full Text] [Related]
38. An Observational Study Assessing Changes in Health and Functional Status in Patients with Chronic Obstructive Pulmonary Disease (COPD) During Therapy with Spiolto
Kosmas E; Titopoulos I; Patentalakis G; Nikas N
Pulm Ther; 2021 Dec; 7(2):429-443. PubMed ID: 33939158
[TBL] [Abstract][Full Text] [Related]
39. Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines.
Kankaanranta H; Harju T; Kilpeläinen M; Mazur W; Lehto JT; Katajisto M; Peisa T; Meinander T; Lehtimäki L
Basic Clin Pharmacol Toxicol; 2015 Apr; 116(4):291-307. PubMed ID: 25515181
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
